How Nav1.8 Painkillers Work Without Causing Addiction

A New Class of Painkiller

For more than two decades, doctors treating moderate-to-severe pain had essentially two options: opioids, which carry serious addiction risk, or over-the-counter drugs like ibuprofen, which often fall short. That gap closed when the U.S. Food and Drug Administration approved suzetrigine, sold as Journavx, in January 2025—the first entirely new type of painkiller to reach the market in over 20 years.

What makes suzetrigine different is not just branding. It belongs to a fundamentally new drug class: selective Nav1.8 sodium channel inhibitors. Understanding how these channels work reveals why the drug can match opioid-strength pain relief without triggering dependence.

What Is Nav1.8 and Why Does It Matter?

The human body uses voltage-gated sodium channels to transmit electrical signals along nerves. There are nine subtypes, labeled Nav1.1 through Nav1.9, each with a different role. Nav1.8 sits exclusively on peripheral sensory neurons—the nerve cells that detect pain in skin, muscles, and organs and relay signals toward the spinal cord and brain.

Crucially, Nav1.8 is not expressed in the brain or heart. This makes it an ideal drug target. Blocking it interrupts pain signals at their source without affecting the central nervous system, which is where opioids act and where addiction pathways live.

How the Drug Blocks Pain

Suzetrigine works by binding to a specific region of the Nav1.8 channel called the second voltage-sensing domain (VSD2). When the drug locks onto this site, it stabilizes the channel in its closed configuration. With the channel shut, sodium ions cannot flow into the nerve cell, and the electrical impulse that would normally carry a pain signal simply never fires.

Because the drug acts only on peripheral nociceptors—specialized pain-detecting neurons—it does not cross the blood-brain barrier. Patients experience pain relief without sedation, euphoria, dizziness, or the respiratory depression that makes opioid overdoses lethal.

How It Compares to Opioids

Opioids like hydrocodone (Vicodin) and oxycodone bind to mu-opioid receptors in the brain. While effective at dulling pain, they simultaneously activate the brain's reward circuitry, releasing dopamine and creating the pleasurable sensation that drives repeated use and, eventually, addiction. The U.S. opioid crisis, which has claimed hundreds of thousands of lives, is a direct consequence of this mechanism.

In two Phase 3 clinical trials, suzetrigine matched hydrocodone-acetaminophen in pain reduction—typically bringing scores down from 7 to 4 on a standard 10-point scale—with no evidence of addictive potential. A 2026 Phase 4 study found that 90.9% of patients recovering from plastic surgery procedures remained completely opioid-free through the end of treatment when using suzetrigine.

Limitations and What Comes Next

Suzetrigine is currently approved only for acute pain—short-term pain from surgery, injury, or medical procedures. Chronic pain remains a harder challenge. A Phase 2 trial in patients with lower-back nerve pain (lumbosacral radiculopathy) showed pain reduction, but the placebo group improved by a similar amount, according to Science. Vertex Pharmaceuticals continues Phase 3 trials for diabetic nerve pain, with results expected to clarify whether the drug can expand beyond acute use.

Other companies are also pursuing Nav1.8. Latigo Biotherapeutics reported positive early results for its own Nav1.8 blocker, LTG-001, and began safety testing of a second compound targeting chronic pain. The competitive landscape suggests that Nav1.8 inhibitors could eventually become a broad drug class, much as statins did for cholesterol.

Why It Matters

The significance of Nav1.8 painkillers extends beyond pharmacology. The opioid epidemic cost the United States an estimated $1.5 trillion in 2020 alone, according to a congressional report. A non-addictive painkiller that genuinely works for moderate-to-severe pain could reshape post-surgical care, emergency medicine, and chronic pain management—reducing both human suffering and the societal costs of addiction.

For the first time in a generation, patients and doctors have a credible alternative that treats serious pain without the shadow of dependence.